Abstract
Purpose
To evaluate the safety and efficacy of intravitreal injection of bevacizumab advanced to vitrectomy for severe proliferative diabetic retinopathy.
Methods
Eight eyes of six patients (33–64 years old, all male patients) with severe proliferative diabetic retinopathy were investigated. An intravitreal injection of 1.25 mg bevacizumab was performed 3–30 days prior to planned vitrectomy.
Results
All cases showed minimum bleeding during surgical dissection of fibrovascular membrane. Two cases receiving bevacizumab 7 days before the surgery showed strong fibrosis and adhesion of fibrovascular membrane, resulted in some surgical complications. The cases having intravitreal bevacizumab for shorter time did not show extensive fibrosis.
Conclusions
The pretreatment of bevacizumab is likely effective in the vitrectomy for severe PDR. The appropriate timing of vitrectomy after bevacizumab injection should be further evaluated.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Fong DS, Aiello LP, Ferris III FL, Klein R . Diabetic retinopathy. Diabetes Care 2004; 27 (10): 2540–2553.
Joussen AM, Joeres S . Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol 2007; 39: 69–87.
Helbig H, Kellner U, Bornfeld N, Foerster MH . Vitrectomy in diabetic retinopathy: outcome, risk factors, complications. Klin Monatsbl Augenheilkd (Written In German) 1998; 212 (5): 339–342.
Kramer I, Lipp HP . Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32 (1): 1–14.
Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113 (10): 1695.e1–1695.e15.
Chen E, Park CH . Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26 (6): 699–700.
Mason III JO, Nixon PA, White MF . Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142 (4): 685–688.
Luke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26 (9): 999–1005.
Scott GI . Ocular complications of diabetes mellitus. Br J Ophthalmol 1953; 37 (12): 705–715.
Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S . Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26 (8): 871–876.
Gibran SK, Sachdev A, Stappler T, Newsome R, Wong D, Hiscott P . Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol 2007; 91 (5): 602–604.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishikawa, K., Honda, S., Tsukahara, Y. et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 23, 108–111 (2009). https://doi.org/10.1038/sj.eye.6702983
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6702983
Keywords
This article is cited by
-
Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023
International Journal of Retina and Vitreous (2023)
-
Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Eye and Vision (2022)
-
Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial
International Journal of Retina and Vitreous (2021)
-
Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy
Eye (2019)
-
Frequency and Risk Factors for Neovascular Glaucoma After Vitrectomy in Eyes with Diabetic Retinopathy: An Observational Study
Diabetes Therapy (2019)
